Dermatology

JAK Inhibitors

Questions discussed in this category

What is your experience with using oral deucravacitinib off label for conditions such as recalcitrant facial discoid lupus or recalcitrant lichen planus?

Do you have thoughts in general about the potential of TYK2 inhibition for these difficult to treat diseases?This question is part of a collaboration ...

1 Answer available

Do patient co-morbidities impact when you prescribe oral jak inhibitors?

Are you less likely to prescribe it for patients with dyslipidemia or autoimmune disease?

3 Answers available

What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?

1 Answer available

Do you have concerns with the use of oral contraceptives in patients on JAK inhibitors given the black box warning for thromboembolic events?

How has this impacted your counseling and management?

2 Answers available

Papers discussed in this category

Annals of the rheumatic diseases, 2023 May 29

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Autoimmunity reviews, 2023 Dec 20

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.

Dermatology

JAK Inhibitors

Questions discussed in this category

Papers discussed in this category

Related Topics in Dermatology